These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 30785319)

  • 21. Role of Devices in Insulin Delivery.
    Meneghini LF; McNulty JN
    Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052
    [No Abstract]   [Full Text] [Related]  

  • 22. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2019 Feb; 21(S1):S57-S78. PubMed ID: 30785319
    [No Abstract]   [Full Text] [Related]  

  • 23. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2018 Feb; 20(S1):S55-S70. PubMed ID: 29437477
    [No Abstract]   [Full Text] [Related]  

  • 24. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2017 Feb; 19(S1):S42-S58. PubMed ID: 28192016
    [No Abstract]   [Full Text] [Related]  

  • 25. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
    [No Abstract]   [Full Text] [Related]  

  • 26. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2020 Feb; 22(S1):S32-S46. PubMed ID: 32069160
    [No Abstract]   [Full Text] [Related]  

  • 27. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
    Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilar insulins are coming: what they are, what you need to know.
    Edelman S; Polonsky WH; Parkin CG
    Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SAR342434 - an insulin biosimilar for the treatment of type II diabetes.
    Hu J; Wang M; Zhao Y
    Expert Opin Biol Ther; 2018 Nov; 18(11):1107-1112. PubMed ID: 30295083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction of biosimilar insulins in Europe.
    Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
    Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilar insulins: guidance for data interpretation by clinicians and users.
    Heinemann L; Home PD; Hompesch M
    Diabetes Obes Metab; 2015 Oct; 17(10):911-8. PubMed ID: 25974131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilar insulins.
    Heinemann L
    Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes.
    Crasto W; Jarvis J; Khunti K; Davies MJ
    Postgrad Med J; 2009 May; 85(1003):257-67. PubMed ID: 19520878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administration of Biosimilar Insulin Analogs: Role of Devices.
    Heinemann L; Fritz I; Khatami H; Edelman SV
    Diabetes Technol Ther; 2017 Feb; 19(2):79-84. PubMed ID: 28118050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin Pumps.
    Pickup JC
    Diabetes Technol Ther; 2018 Feb; 20(S1):S30-S40. PubMed ID: 29437475
    [No Abstract]   [Full Text] [Related]  

  • 36. [New guideline for the treatment of diabetes mellitus type 1].
    Hinneburg I
    Med Monatsschr Pharm; 2012 Feb; 35(2):61-4. PubMed ID: 22400431
    [No Abstract]   [Full Text] [Related]  

  • 37. Diabetes Technology and Therapy in the Pediatric Age Group.
    Maahs DM; Shalitin S
    Diabetes Technol Ther; 2018 Feb; 20(S1):S114-S127. PubMed ID: 29437470
    [No Abstract]   [Full Text] [Related]  

  • 38. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
    Rasmussen JT; Ipema HJ
    Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.